CDC-RFA-CK-23-0003: Strengthening Global Capacity for Molecular Surveillance and Outbreak Response for Enteric Diseases
Closed
This grant is closed. A newer notice from the same program is forecast: Capacity Building for National Immunization Programs in the Eastern Mediterranean Region (CDC-RFA-JG-27-0070). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control - NCEZID notices from 2023.
Centers for Disease Control - NCEZID offered grants to any type of organization. It expected to make about 3 awards worth $30.0 million in total. Applications closed on May 15, 2023.
From the official notice on Grants.gov, last changed April 18, 2023. Checked November 7, 2026.
- Total funding$30.0 million
- Expected awards3
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 15, 2023 |
|---|---|
| Deadline | May 15, 2023 |
| Archived by Grants.gov | June 14, 2023 |
Who can apply
This opportunity was open to any type of organization.
All 8 applicant types the notice lists
- State governments
- Public and State controlled institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Complete applications should include: table of contents, project abstract, project narrative (including work plan), budget narrative, letters of support, CVs/resumes, organizational charts, copy of indirect cost-rate agreement, and memorandum of agreement or memorandum of understanding, if applicable. If any of these documents are missing, the application will be deemed non-responsive and not be passed along for further review.
Is this a realistic fit?
- Most of the program's money (49% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The purpose of this NOFO is to strengthen global capacity for molecular surveillance and outbreak response for enteric diseases. The Surveillance strategy will include the following activities: 1) Capacity building for enteric disease surveillance, including case confirmation. 2) Wastewater and Environmental Surveillance capacity building; 3) Regional capacity building for Whole Genome Sequencing (WGS), bioinformatics, lab diagnosis and outbreak preparedness; 4) Country-level WGS and lab diagnosis capacity building. The Outbreak Response strategy will include the following activities: 1) Regional enteric disease outbreak response technical assistance; 2) Country-level Water, Sanitation, and Hygiene (WASH) program capacity building; and 3) Epidemiology and laboratory workforce development for enteric diseases. Locations of activities will vary geographically to include multiple regional and country-level locations, based on CDC priority.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before
From fiscal 2021 to 2025, Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security (93.318) awarded $1.3 billion across 306 grant awards, an average of $4.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| African Field Epidemiology Network LTD | 6 | $147 million | |
| The Task Force for Global Health, Inc. | Georgia | 7 | $138 million |
| World Health Organization, Somalia | 14 | $125 million | |
| Association of Public Health Laboratories, Inc. (the) | Maryland | 3 | $61.5 million |
| The Johns Hopkins University | Maryland | 5 | $42.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0070, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CK-23-0003 still open?
No. It closed on May 15, 2023. A newer notice is forecast: CDC-RFA-JG-27-0070, expected deadline February 12, 2027.
Who can apply for Strengthening Global Capacity for Molecular Surveillance and Outbreak Response for Enteric Diseases?
Centers for Disease Control - NCEZID accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Strengthening Global Capacity for Molecular Surveillance and Outbreak Response for Enteric Diseases?
Closed May 15, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $30.0 million in total across about 3 awards.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before?
The largest recipients over five fiscal years were African Field Epidemiology Network LTD, The Task Force for Global Health, Inc., World Health Organization, Somalia. The program made 306 awards worth $1.3 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)